Evidence map›Paper›PMID 40385402›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Cardiovascular risk management in adults with diagnosed diabetes in Mexico from 2016-2023: A retrospective analysis of nationally representative surveys.

Daniel Ramírez-García, Jerónimo Perezalonso-Espinosa, Padme Nailea Méndez-Labra, Carlos A Fermín-Martínez, Juan Pablo Díaz-Sánchez, César Daniel Paz-Cabrera, Arsenio Vargas-Vázquez, Miriam Teresa López-Teros, David Flood, Jennifer Manne-Goehler and 4 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Daniel Ramírez-GarcíaResearch Division, Instituto Nacional de Geriatría, Mexico City, Mexico.ORCID 0000-0002-6899-246X
Jerónimo Perezalonso-EspinosaResearch Division, Instituto Nacional de Geriatría, Mexico City, Mexico.
Padme Nailea Méndez-LabraResearch Division, Instituto Nacional de Geriatría, Mexico City, Mexico.
Carlos A Fermín-MartínezResearch Division, Instituto Nacional de Geriatría, Mexico City, Mexico.ORCID 0000-0001-5627-8851
Juan Pablo Díaz-SánchezResearch Division, Instituto Nacional de Geriatría, Mexico City, Mexico.
César Daniel Paz-CabreraResearch Division, Instituto Nacional de Geriatría, Mexico City, Mexico.ORCID 0000-0003-0678-4830
Arsenio Vargas-VázquezFacultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico.ORCID 0000-0002-0051-7689
Miriam Teresa López-TerosNutrition Division, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.ORCID 0009-0000-3741-8804
David FloodDepartment of Medicine, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0002-4372-7387
Jennifer Manne-GoehlerDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0001-9295-0035
Neftali Eduardo Antonio-VillaDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health.ORCID 0000-0002-6879-1078
Goodarz DanaeiDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health.ORCID 0000-0003-2456-5463
Jacqueline A SeiglieDiabetes Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0001-9278-4516
Omar Yaxmehen Bello-ChavollaResearch Division, Instituto Nacional de Geriatría, Mexico City, Mexico.ORCID 0000-0003-3093-937X

Funding

REACH-Es: Adapting a digital health tool to improve diabetes medication adherence among Latino adultsK23DK135798 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Jacqueline Anne Seiglie · 2023 to 2026
$784k
NIDDK NIH HHS K23 DK135798
6 · The paper itself

Abstract

backgroundEffective cardiovascular disease (CVD) risk management is a cornerstone of optimal diabetes care. Here, we estimated the prevalence and determinants of CVD risk factor control amongst individuals with diagnosed diabetes in Mexico.

methodsWe analyzed data from individuals with diagnosed diabetes ≥20 years from the 2016-2023 Mexican National Health and Nutrition Surveys. We estimated the prevalence of glycemic, blood pressure (BP), non-current smoking, and combined CVD risk factor control. LDL-C control was assessed using SCORE2-Diabetes risk categories. We estimated the prevalence of BP-lowering, cholesterol-lowering, and glucose-lowering medication use, and explored determinants of control achievement using logistic regression.

resultsWe analyzed data representing 43.2 million adults with diagnosed diabetes during 2016-2023. In 2023, glycemic control was 29% (95%CI 21%-38%), BP control 22.9% (95%CI 14%-31%), and non-current smoking 89% (95%CI 81%-96%). The proportion of people classified as high or very-high CVD risk increased from 59.8% (95%CI 52.1%-67.0%) in 2016 to 68.4% (95%CI 55.6%-78.9%) in 2023, representing ~5.1 million adults. LDL-C control prevalence increased from 2.8% (95%CI 1.2%-4.4%) in 2016 to 6.6% (95%CI 1.9%-11.2%) in 2023. Combined risk factor control achievement was low primarily due to suboptimal LDL-C control, despite high medication use; this was more likely achieved in females, younger individuals, and those with college education or living in states with higher socioeconomic position.

conclusionsDespite increasing CVD risk during this period, comprehensive glycemic and CVD risk factor management for adults with diabetes in Mexico remains suboptimal. Our findings highlight the need for strategies to address gaps in CVD risk management to reduce premature mortality in this population.

Indexed as

blood pressureCVD riskDiabetesglycemic controlLDL-C controlMexico

Identifiers

PMID40385402
PMCPMC12083602

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.